354 related articles for article (PubMed ID: 33367720)
1. Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria.
D'Costa MR; Kausz AT; Carroll KJ; Ingimarsson JP; Enders FT; Mara KC; Mehta RA; Lieske JC
Nephrol Dial Transplant; 2021 Dec; 36(12):2208-2215. PubMed ID: 33367720
[TBL] [Abstract][Full Text] [Related]
2. Etiology, urine metabolic risk factors, and urine oxalate patterns in patients with significant hyperoxaluria and recurrent nephrolithiasis.
Moore JP; Mauler DJ; Narang GL; Stern KL; Humphreys MR; Keddis MT
Int Urol Nephrol; 2022 Nov; 54(11):2819-2825. PubMed ID: 35917078
[TBL] [Abstract][Full Text] [Related]
3. Defining variation in urinary oxalate in hyperoxaluric stone formers.
Antonelli JA; Langman CB; Odom C; Poindexter J; Huet B; Pearle MS
J Endourol; 2013 Dec; 27(12):1530-4. PubMed ID: 24147733
[TBL] [Abstract][Full Text] [Related]
4. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease.
Perinpam M; Enders FT; Mara KC; Vaughan LE; Mehta RA; Voskoboev N; Milliner DS; Lieske JC
Clin Biochem; 2017 Dec; 50(18):1014-1019. PubMed ID: 28764885
[TBL] [Abstract][Full Text] [Related]
5. Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.
Sas DJ; Mara K; Mehta RA; Seide BM; Banks CJ; Danese DS; McGregor TL; Lieske JC; Milliner DS
Pediatr Nephrol; 2024 Jan; 39(1):141-148. PubMed ID: 37458799
[TBL] [Abstract][Full Text] [Related]
6. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria.
Arnous MG; Vaughan L; Mehta RA; Schulte PJ; Lieske JC; Milliner DS
J Urol; 2023 Jun; 209(6):1141-1150. PubMed ID: 36888927
[TBL] [Abstract][Full Text] [Related]
8. Intestinal Oxalate Absorption, Enteric Hyperoxaluria, and Risk of Urinary Stone Formation in Patients with Crohn's Disease.
Siener R; Ernsten C; Speller J; Scheurlen C; Sauerbruch T; Hesse A
Nutrients; 2024 Jan; 16(2):. PubMed ID: 38257157
[TBL] [Abstract][Full Text] [Related]
9. ALLN-177, oral enzyme therapy for hyperoxaluria.
Lingeman JE; Pareek G; Easter L; Pease R; Grujic D; Brettman L; Langman CB
Int Urol Nephrol; 2019 Apr; 51(4):601-608. PubMed ID: 30783888
[TBL] [Abstract][Full Text] [Related]
10. Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols.
Rodgers AL; Allie-Hamdulay S; Jackson GE; Sutton RA
J Endourol; 2014 Aug; 28(8):985-94. PubMed ID: 24773381
[TBL] [Abstract][Full Text] [Related]
11. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass.
Nelson WK; Houghton SG; Milliner DS; Lieske JC; Sarr MG
Surg Obes Relat Dis; 2005; 1(5):481-5. PubMed ID: 16925274
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
Hoppe B; Groothoff JW; Hulton SA; Cochat P; Niaudet P; Kemper MJ; Deschênes G; Unwin R; Milliner D
Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
[TBL] [Abstract][Full Text] [Related]
13. Use of a probiotic to decrease enteric hyperoxaluria.
Lieske JC; Goldfarb DS; De Simone C; Regnier C
Kidney Int; 2005 Sep; 68(3):1244-9. PubMed ID: 16105057
[TBL] [Abstract][Full Text] [Related]
14. End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.
Langman CB; Assimos D; Blank M; Calle J; Grauer A; Kausz A; Milliner D; Nazzal L; Smith K; Tasian G; Thompson A; Wood KD; Worcester E; Yang S; Malley MA; Knauf F; Lieske JC;
Clin J Am Soc Nephrol; 2023 Dec; 18(12):1637-1644. PubMed ID: 37342976
[TBL] [Abstract][Full Text] [Related]
15. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
[TBL] [Abstract][Full Text] [Related]
16. An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria.
Lubkowicz D; Horvath NG; James MJ; Cantarella P; Renaud L; Bergeron CG; Shmueli RB; Anderson C; Gao JR; Kurtz CB; Perreault M; Charbonneau MR; Isabella VM; Hava DL
Mol Syst Biol; 2022 Mar; 18(3):e10539. PubMed ID: 35253995
[TBL] [Abstract][Full Text] [Related]
17. Dietary risk factors for hyperoxaluria in calcium oxalate stone formers.
Siener R; Ebert D; Nicolay C; Hesse A
Kidney Int; 2003 Mar; 63(3):1037-43. PubMed ID: 12631085
[TBL] [Abstract][Full Text] [Related]
18. The urinary response to an oral oxalate load in recurrent calcium stone formers.
Krishnamurthy MS; Hruska KA; Chandhoke PS
J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
[TBL] [Abstract][Full Text] [Related]
19. Comparison of renal function and metabolic abnormalities of cystine stone patients and calcium oxalate stone patients in China.
Shen L; Sun X; Zhu H; Cong X; Ning B
World J Urol; 2013 Oct; 31(5):1219-23. PubMed ID: 22622395
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for developing renal stones in inflammatory bowel disease.
McConnell N; Campbell S; Gillanders I; Rolton H; Danesh B
BJU Int; 2002 Jun; 89(9):835-41. PubMed ID: 12010224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
